Baidu
map

移动电子病历系统厂商Modernizing Medicine获3800万美元投资

2015-09-27 池岳斌 贝壳社

根据美国证券交易委员会的文件,位于佛罗里达州博卡拉顿的Modernizing Medicine获得了3800万美元的股权投资。 根据相关披露的信息,包括Pentland Group和Summit Partners以及Sands Capital Ventures旗下的基金都参与本轮融资。这使该公司的累积融资金额达到了8700万美元。 Modernizing Medicine手






根据美国证券交易委员会的文件,位于佛罗里达州博卡拉顿的Modernizing Medicine获得了3800万美元的股权投资。

根据相关披露的信息,包括Pentland Group和Summit Partners以及Sands Capital Ventures旗下的基金都参与本轮融资。这使该公司的累积融资金额达到了8700万美元。

Modernizing Medicine手机电子医疗记录,又称为电子助理系统(EMA),针对专家开发。他们使用汇总的,识别的数据去创建群体见解,然后将之传输回医生。

该公司表示该系统适用于许多市场包括皮肤、眼科、骨科、耳鼻喉科、胃肠病学,泌尿外科,整形外科,且在美国超过9000供应商正在使用。

Modernizing Medicine联合创始人兼首席执行官Daniel Cane表示:“我们非常感谢大家对Modernizing Medicine未来的增长投信任票。虽然我们对专业特有的供应商市场的贡献已经被相当可观的成绩所证明,为医生和病人提高治疗效率和治疗效果仍旧是一个机会。”

在公司3月份宣布的前一轮融资中,Modernizing Medicine 受到了一份来自IBM的投资——通过其1亿美元的投资基金seed Watson innovations。

当时,该公司表示,他们正在开发一个新app作为IBM沃森的生态系统项目的一部分,这被称为schEMA,他将建立在工作EMA和汇总EHR数据,但是加入沃森的解析非结构化数据的能力,这能给医学专家为病人提供最佳治疗方案的数据。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858628, encodeId=446618586287b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Oct 15 11:20:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773505, encodeId=fd8e1e735050a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 26 23:20:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37960, encodeId=61bc3e960a4, content=很好的文章哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Oct 07 21:59:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577437, encodeId=570c15e743711, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606627, encodeId=350d160662e6d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37515, encodeId=f8cb3e515fb, content=好信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Sep 27 21:32:00 CST 2015, time=2015-09-27, status=1, ipAttribution=)]
    2015-10-15 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858628, encodeId=446618586287b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Oct 15 11:20:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773505, encodeId=fd8e1e735050a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 26 23:20:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37960, encodeId=61bc3e960a4, content=很好的文章哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Oct 07 21:59:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577437, encodeId=570c15e743711, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606627, encodeId=350d160662e6d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37515, encodeId=f8cb3e515fb, content=好信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Sep 27 21:32:00 CST 2015, time=2015-09-27, status=1, ipAttribution=)]
    2015-11-26 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858628, encodeId=446618586287b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Oct 15 11:20:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773505, encodeId=fd8e1e735050a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 26 23:20:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37960, encodeId=61bc3e960a4, content=很好的文章哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Oct 07 21:59:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577437, encodeId=570c15e743711, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606627, encodeId=350d160662e6d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37515, encodeId=f8cb3e515fb, content=好信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Sep 27 21:32:00 CST 2015, time=2015-09-27, status=1, ipAttribution=)]
    2015-10-07 hlycom3356

    很好的文章哦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1858628, encodeId=446618586287b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Oct 15 11:20:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773505, encodeId=fd8e1e735050a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 26 23:20:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37960, encodeId=61bc3e960a4, content=很好的文章哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Oct 07 21:59:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577437, encodeId=570c15e743711, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606627, encodeId=350d160662e6d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37515, encodeId=f8cb3e515fb, content=好信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Sep 27 21:32:00 CST 2015, time=2015-09-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858628, encodeId=446618586287b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Oct 15 11:20:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773505, encodeId=fd8e1e735050a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 26 23:20:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37960, encodeId=61bc3e960a4, content=很好的文章哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Oct 07 21:59:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577437, encodeId=570c15e743711, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606627, encodeId=350d160662e6d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37515, encodeId=f8cb3e515fb, content=好信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Sep 27 21:32:00 CST 2015, time=2015-09-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1858628, encodeId=446618586287b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Oct 15 11:20:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773505, encodeId=fd8e1e735050a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 26 23:20:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37960, encodeId=61bc3e960a4, content=很好的文章哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Oct 07 21:59:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577437, encodeId=570c15e743711, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606627, encodeId=350d160662e6d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 29 12:20:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37515, encodeId=f8cb3e515fb, content=好信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Sep 27 21:32:00 CST 2015, time=2015-09-27, status=1, ipAttribution=)]
    2015-09-27 lovetcm

    好信息

    0

相关资讯

医院泄露个人电子病历将被追责

5月13日,国家卫生和计划生育委员会发布《人口健康信息管理办法(试行)》向社会公开征求意见。在不少业内外人士先后涉足医疗大数据的当下,此办法算得上是泼了一盆冷水,从涉及“应用”的条款不难发现行政之手仍掌握了不小权利。 以下是卫计委官方网站发布的《人口健康信息管理办法(试行)》解读。 一、出台《人口健康信息管理办法(试行)》的背景 随着人口健康信息化建设全面快速推进和新技术快速发展与应用,全国各

电子病历让医生抓狂?

电子病历的应用越来越广,其优缺点也逐渐明了。启用电子病历,医生的“天书”成了历史。普遍认为,电子病历可以帮助医生更好地进行医疗工作。事实果真如此吗?医生对电子病历满意吗?实际情况可能令你大跌眼镜!  近日,美国医学会(AMA)和美国内科医生学会(ACP)的一个分支——美国电子病历分会发表了一份名为“2014年医生使用电子病历情况”的报告。报告中的数据显示: 42%的受访医生认为他

谷歌眼镜:颠覆电子病历的节奏

医生带着智能眼镜为病人检查身体的时代似乎与我们越来越近。旧金山可穿戴技术创业公司Augmedix近日获得投资基金DCM和 Emergence Capital Partners 320万美元的投资。Augmedix正在为谷歌眼镜(Google Glass)开发临床应用,并与全美范围内的医生合作,将配有这些应用的谷歌眼镜推荐给他们。配备了临床应用的谷歌眼镜对医生来说好处很多:它几乎解放了双手,医生在诊

内科-儿科医生远远超过精神科医生成为电子病历的很大用户

内科医生-儿科医生列为电子健康记录(EHR)系统的最大用户,精神科医生和整体的执业医师在该系统中殿后,本月初调研公司SK&A报道。 调查以SK&A巨大的电话调研团队,于2014年的后半年拜访约281000家医疗机构约750000名对症疗法和整骨疗法的医生,营销公司的高级经理杰克指出。 内科-儿科结合专业医师在 EHR技术的使用率最高为76%,其次是放射科71%,泌尿科、病理

零售端:移动医疗APP的推广“潜力股”

移动医疗App的推广成本正在变得越来越高。在用户端,靠大打广告,优惠促销刺激等手段虽然可以短期内增加一些新用户,但对长期的用户依从性并没有太大作用。而在医生端,采用类似药品销售的地推方式成本极高,正在逐渐变成海选,怎样让医生真正觉得工具有用并使用下去是一个大问题。美国的移动医疗快速发展的一个重要特征就是,产品设计固然是第一环,但后面的渠道建设起到的决定性作用越来越明显。渠道策略的一种途径就是找最专

苹果HealthKit成功整合电子病历,将来有望改变移动医疗版图

这家科技巨头连接了健康追踪软件Healthkit和位于洛杉矶的赛达斯-西奈医疗中心(Cedars-Sinai Medical Center )的病历档案,这也是迄今为止苹果在健康领域发起的最大规模的整合。 西奈医疗中心首席信息官Darren Dworkin在采访中透露,本周医院升级电子病历系统后,将为超过8万名患者开放HealthKit通道。“我们并不完全清楚病人将会如何使用这项功能,但我们

Baidu
map
Baidu
map
Baidu
map